213 related articles for article (PubMed ID: 27472228)
21. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
Jørgensen JT
Expert Rev Mol Diagn; 2016; 16(2):131-3. PubMed ID: 26559787
[TBL] [Abstract][Full Text] [Related]
22. [Biological follow-up of patients with HIV treated with anti-PD-1 or anti-PD-L1 for non-small cell bronchial carcinoma: A task group proposal].
Guihot A; Cadranel J; Lambotte O; Lavolé A; Autran B; Spano JP
Rev Mal Respir; 2016 Jun; 33(6):419-21. PubMed ID: 27140903
[No Abstract] [Full Text] [Related]
23. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
[No Abstract] [Full Text] [Related]
24. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
25. [Immuno-Oncology therapeutic principles in lung and renal cell carcinoma].
Wolf J; Grünwald V
Oncol Res Treat; 2014; 37 Suppl 4():10-3. PubMed ID: 25301191
[No Abstract] [Full Text] [Related]
26. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
[TBL] [Abstract][Full Text] [Related]
27. More Benefits for Checkpoint Inhibitors in NSCLC.
Cancer Discov; 2015 Dec; 5(12):OF2. PubMed ID: 26511141
[TBL] [Abstract][Full Text] [Related]
28. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
Pennell NA
Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
[TBL] [Abstract][Full Text] [Related]
29. Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies.
Amaya CN; Wians FH; Bryan BA; Torabi A
Pathology; 2017 Apr; 49(3):292-296. PubMed ID: 28238417
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Dang TO; Ogunniyi A; Barbee MS; Drilon A
Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
[TBL] [Abstract][Full Text] [Related]
31. The science of checkpoint inhibition in kidney cancer.
Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
[No Abstract] [Full Text] [Related]
32. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Monteiro ID; Califano R; Mountzios G; de Mello RA
Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitors in lung cancer: past, present and future.
Seetharamu N; Budman DR; Sullivan KM
Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
[TBL] [Abstract][Full Text] [Related]
35. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
36. Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy.
Basin S; Perrin J; Michot JM; Lambotte O; Cauquil C
Eur J Cancer; 2021 Mar; 145():230-233. PubMed ID: 33517201
[No Abstract] [Full Text] [Related]
37. Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.
Pellegrino B; Musolino A; Tiseo M
Ann Oncol; 2017 Jun; 28(6):1405-1406. PubMed ID: 28383638
[No Abstract] [Full Text] [Related]
38. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
39. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
40. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.
Champiat S; Ileana E; Giaccone G; Besse B; Mountzios G; Eggermont A; Soria JC
J Thorac Oncol; 2014 Feb; 9(2):144-53. PubMed ID: 24419410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]